N
Neurogene Inc. (NGNE)
NGM – Real Time Price. Currency in USD
32.03
+1.62 (5.33%)
At close: Jun 26, 2026, 4:00 PM EDT
31.61
-0.42 (-1.31%)
After-hours: Jun 26, 2026, 7:28 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
32.03
+1.62 (5.33%)
At close: Jun 26, 2026, 4:00 PM EDT
31.61
-0.42 (-1.31%)
After-hours: Jun 26, 2026, 7:28 PM EDT
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
| Name | Position |
|---|---|
| Dr. Andrew E. Mulberg CPI, FAAP, M.D. | Senior VP of Regulatory Affairs, Quality Assurance & Quality Control |
| Dr. Julie Jordan M.D. | Chief Medical Officer |
| Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair & CEO |
| Dr. Stuart Cobb Ph.D. | Chief Scientific Officer |
| Mr. Arvind Sreedharan | Senior Vice President of Business Operations |
| Mr. Ricardo Jimenez | Senior Vice President of Technical Operations |
| Ms. Christina Shafer | Chief Commercial Officer |
| Ms. Christine Mikail Cvijic J.D. | President, CFO & Director |
| Ms. Donna M. Cochener-Metcalfe J.D., L.L.M. | Senior VP, General Counsel & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-06-08 | 8-K | ngne-20260608.htm |
| 2026-06-04 | 8-K | ngne-20260603.htm |
| 2026-05-12 | 8-K | ngne-20260512.htm |
| 2026-05-12 | 10-Q | ngne-20260331.htm |
| 2026-04-20 | 8-K | ngne-20260420.htm |
| 2026-04-16 | DEFA14A | a2026defa14a_notice.htm |
| 2026-04-16 | ARS | ef20070648_ars.pdf |
| 2026-03-24 | S-8 | neurogene-sx8xmarch2026.htm |
| 2026-03-24 | 8-K | ngne-20260324.htm |
| 2026-03-24 | 10-K | ngne-20251231.htm |